Transgene has recently announced that pre-clinical results of two of its immunotherapeutic programs will be presented at the American Association for Cancer Research (AACR) Annual Meeting that will take place Philadelphia, between the 18th and the 22nd of April, 2015.
The company’s platforms utilize viral vector equipment to kill infected or malignant cells, with its two lead clinical-stage programs corresponding to TG4010 (targeting non-small cell lung cancer (NSLC)) and Pexa-Vec for the treatment of liver cancer.
According to a recent news release, the company will present late-stage results data on their TG4010 for NSCL. The poster will be presented on Monday the 20th of April and the abstract (#2497) is titled “Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer.”
TG4010 is a new MUC1 targeting immunotherapy for the treatment of metastatic NSCLC in combination with first-line chemotherapy. TG4010 is a recombinant vaccinia virus of the Ankara strain (MVA) expressing the coding sequences of the MUC1 antigen and of the cytokine Interleukin-2 (IL2). In addition to NSCLC, MUC1 TAA is expressed in other solid tumors including breast, colorectal, kidney and prostate cancers.
Transgene will also present pre-clinical stage data on TG3003, an anti-cancer monoclonal antibody, on Sunday the 19th of April. The abstract (#288), titled “TG3003, an immunomodulatory anti-CD115 mAb targeting M2-macrophage polarization in the tumor microenvironment” will focus on TG3003, a monoclonal antibody currently in pre-clinical development that directly targets human CD115, a CSF-1 cell-surface receptor expressed by all types of myeloid cells, including macrophages.
The compound had been found to prevent the formation of M2-macrophages and to favor the generation of M1-macrophages and dendritic cells, stimulating the immune response against cancer. Results from other studies also found that the compound can target osteoclasts, myeloid cells that cause metastasis-induced bone degradation and pain in patients with cancer.
The company will also present a third poster that reviews clinical experience with their modified vaccinia virus called Ankara (MVA). The abstract (#2498) titled “The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies,” will be presented on Monday the 20th of April.
More information about the presentations can be found in the AACR website at: www.aacr.org.